Study of biomarkers symmetric dimethylarginine (SDMA), serum inosine and serum and urinary Cystatin B in healthy dogs

• Grant number: 19/25789-2
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: March 01, 2020
• End date: December 31, 2021
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Priscylla Tatiana Chalfun Guimaraes-Okamoto
• Grantee: Lucas Franco Miranda Ribeiro
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

The worsening in renal function results in decreased glomerular filtration rate (GFR)which within days the process of Acute Renal Injury occurs. The International Renal Interest Society (IRIS) defines AKI as the sudden reduction in urine output associated with a progressive increase in 0.3 mg/dL of serum creatinine concentration within 48hours, even in non-azotemia animals. However, serum creatinine is a poor marker of GFR, because in addition to increasing their concentrations when 75% of nephrons fail, this marker can still be influenced by several extrarenal causes. Currently, human and veterinary medicine research, seek the perfect mapping of the real renal function of these patients through guidelines and new biomarkers in order to institute early treatment, its monitoring and prognosis. When dependent only on serum creatinine and urine output, the patients are prone to late-stage treatment and reserved prognosis with the risk of imminent death. Thus, this study aims to evaluate and correlate the serum concentrations of the biomarker's symmetric dimethylarginine (SDMA), serum inosine and cystatin B urinary in healthy dogs.